Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 June 2019Published: 24 September 2014
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC